RO7049665/IgG-IL2/ IgG-IL2ND2 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 95 | 自己免疫性肝炎 | 4 |
95. 自己免疫性肝炎
臨床試験数 : 52 / 薬物数 : 68 - (DrugBank : 27) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 111
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2020-003990-23-DE (EUCTR) | 21/06/2021 | 17/02/2021 | A Study to Investigate the Effect of RO7049665 on the Time to Relapse Following Steroid Tapering in Patients With Autoimmune Hepatitis | A DOUBLE-BLIND, RANDOMIZED,PARALLEL-GROUP, PHASE 2 STUDY TO INVESTIGATE THE EFFECT OF RO7049665 ON THE TIME TO RELAPSE FOLLOWINGSTEROID TAPERING IN PATIENTS WITH AUTOIMMUNE HEPATITIS | Autoimmune Hepatitis (AIH) MedDRA version: 20.1;Level: PT;Classification code 10003827;Term: Autoimmune hepatitis;System Organ Class: 10019805 - Hepatobiliary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: IgG IL2/RO7049665 Product Code: RO7049665 INN or Proposed INN: NA Other descriptive name: RO7049665/IgG-IL2/ IgG-IL2ND2 | F. Hoffmann-La Roche Ltd | NULL | Not Recruiting | Female: yes Male: yes | 84 | Phase 2 | Portugal;Canada;Australia;Netherlands;Germany;United Kingdom;Italy;New Zealand;Korea, Republic of | ||
| 2 | EUCTR2020-003990-23-PT (EUCTR) | 18/06/2021 | 12/03/2021 | A Study to Investigate the Effect of RO7049665 on the Time to Relapse Following Steroid Tapering in Patients With Autoimmune Hepatitis | A DOUBLE-BLIND, RANDOMIZED,PARALLEL-GROUP, PHASE 2 STUDY TO INVESTIGATE THE EFFECT OF RO7049665 ON THE TIME TO RELAPSE FOLLOWINGSTEROID TAPERING IN PATIENTS WITH AUTOIMMUNE HEPATITIS | Autoimmune Hepatitis (AIH) MedDRA version: 20.1;Level: PT;Classification code 10003827;Term: Autoimmune hepatitis;System Organ Class: 10019805 - Hepatobiliary disorders | Product Name: IgG IL2/RO7049665 Product Code: RO7049665 INN or Proposed INN: NA Other descriptive name: RO7049665/IgG-IL2/ IgG-IL2ND2 | F. Hoffmann-La Roche Ltd | NULL | Not Recruiting | Female: yes Male: yes | 84 | Phase 2 | Portugal;Canada;Australia;Netherlands;Germany;United Kingdom;Italy;New Zealand;Korea, Republic of | ||
| 3 | EUCTR2020-003990-23-NL (EUCTR) | 28/04/2021 | 22/02/2021 | A Study to Investigate the Effect of RO7049665 on the Time to Relapse Following Steroid Tapering in Patients With Autoimmune Hepatitis | A DOUBLE-BLIND, RANDOMIZED,PARALLEL-GROUP, PHASE 2 STUDY TO INVESTIGATE THE EFFECT OF RO7049665 ON THE TIME TO RELAPSE FOLLOWINGSTEROID TAPERING IN PATIENTS WITH AUTOIMMUNE HEPATITIS | Autoimmune Hepatitis (AIH) MedDRA version: 20.1;Level: PT;Classification code 10003827;Term: Autoimmune hepatitis;System Organ Class: 10019805 - Hepatobiliary disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Product Name: IgG IL2/RO7049665 Product Code: RO7049665 INN or Proposed INN: NA Other descriptive name: RO7049665/IgG-IL2/ IgG-IL2ND2 | F. Hoffmann-La Roche Ltd | NULL | Not Recruiting | Female: yes Male: yes | 84 | Phase 2 | Portugal;Canada;Australia;Germany;Netherlands;United Kingdom;Italy;New Zealand;Korea, Republic of | ||
| 4 | EUCTR2020-003990-23-IT (EUCTR) | 11/03/2021 | 20/05/2021 | A Study to Investigate the Effect of RO7049665 on the Time to Relapse Following Steroid Tapering in Patients With Autoimmune Hepatitis | A DOUBLE-BLIND, RANDOMIZED,PARALLEL-GROUP, PHASE 2 STUDY TO INVESTIGATE THE EFFECT OF RO7049665 ON THE TIME TO RELAPSE FOLLOWING STEROID TAPERING IN PATIENTS WITH AUTOIMMUNE HEPATITIS - - | Autoimmune Hepatitis (AIH) MedDRA version: 20.1;Level: PT;Classification code 10003827;Term: Autoimmune hepatitis;System Organ Class: 10019805 - Hepatobiliary disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Product Name: IgG IL2/RO7049665 Product Code: [RO7049665] Other descriptive name: RO7049665/IgG-IL2/ IgG-IL2ND2 | F. HOFFMANN - LA ROCHE LTD. | NULL | Not Recruiting | Female: yes Male: yes | 84 | Phase 2 | Portugal;Canada;Korea, Democratic People's Republic of;Australia;Netherlands;Germany;United Kingdom;New Zealand;Italy;Korea, Republic of |